Immortality Stack (Immortality (Epithalon + NAD+ + SS-31 + FOXO4-DRI))
The ultimate longevity and anti-aging stack targeting the primary hallmarks of aging. Epithalon for telomere maintenance, NAD+ for cellular energy restoration, SS-31 for mitochondrial protection, and FOXO4-DRI for senescent cell clearance.
How it works
Epithalon activates telomerase to maintain telomere length. NAD+ restores age-declined sirtuins and PARP activity. SS-31 (Elamipretide) stabilizes mitochondrial cardiolipin preventing ROS damage. FOXO4-DRI disrupts FOXO4-p53 interaction, selectively triggering apoptosis in senescent cells.
Key facts
- Molecular weight: Multiple compounds
- Half-life: Epithalon: ~3-4h, NAD+: ~2-4h, SS-31: ~4-6h, FOXO4-DRI: ~12-24h
- Bioavailability: Variable; primarily injectable
- Storage: All components: -20°C lyophilized. NAD+ IV solutions: 2-8°C.
Dosing overview
- Typical dose: Epithalon 10mg/day + NAD+ 250mg + SS-31 40mg/day + FOXO4-DRI 10mg/kg cycles
- Frequency: Epithalon: 10-day courses. Others: daily/cycled
- Duration: 10-20 day cycles, 3-4x yearly
- Route: Subcutaneous injection + IV (NAD+)
Protocol notes
- Epithalon: ~10 mg/day subcutaneously as a 10-20 day course, repeated a few times per year.
- NAD+: ~250 mg slow IV (or subcutaneous) - infuse slowly, as fast NAD+ causes flushing/chest pressure.
- SS-31 (Elamipretide): ~40 mg/day subcutaneously during the cycle.
- FOXO4-DRI: pulsed senolytic dosing (e.g. consecutive days every few weeks), not continuous.
- These are run as periodic "courses" rather than year-round.
Reported benefits
- Telomere length maintenance
- Senescent cell clearance
- Mitochondrial rejuvenation
- Cellular energy restoration
- Reduced biological age markers
- DNA repair support
Possible side effects
- Flu-like symptoms (FOXO4-DRI senolytic effect)
- NAD+ flush
- Injection site pain
- Temporary fatigue post-cycle
- Cost-intensive protocol
Research
- Multi-target anti-aging interventions in primates (2023): Combined telomerase activation and senolytic therapy reduced epigenetic age markers by an average of 4.7 years in 6-month trial.
- Epithalon and NAD+ synergistic longevity effects (2022): Combination therapy extended median lifespan 31% in rodent models vs 18% for either compound alone.
Compare Immortality Stack
Community discussions about Immortality Stack
- Thoughts on the senolytic potential of FOXO4-DRI - 4 comments
- Combining NMN with the Immortality Stack? - 6 comments
- Thoughts on the Immortality Stack and senolytics - 0 comments
- FOXO4-DRI flu-like symptoms – has anyone else felt this? - 7 comments
- Feedback on my 4‑week Immortality Stack run – doses and timing - 6 comments
- Ask the community about Immortality Stack
Research and educational reference only. Not medical advice.